Recursion(US:RXRX) Ge Long Hui·2025-12-18 09:27Core Viewpoint - Recursion Pharmaceuticals (RXRX.US) has seen a significant stock increase, with an 11.4% rise followed by a 3.8% pre-market gain, driven by an upgrade from Morgan Stanley from "Neutral" to "Overweight" due to the sales potential of its core asset, REC-4881, which is considered to have blockbuster potential [1] Group 1 - Morgan Stanley raised Recursion's target price from $10 to $11, indicating increased confidence in the company's future performance [1] - Cathie Wood has significantly increased her stake in Recursion Pharmaceuticals, acquiring over 2 million shares, signaling strong belief in the company's attractive valuation amidst market downturns [1] - Recursion Pharmaceuticals utilizes machine learning to decode biology, aiming to accelerate drug discovery processes, which positions the company favorably in the biotech industry [1]